Harrow Acquires Santen’s Branded Ophthalmic Portfolio

Harrow announced the signing of agreements with affiliates of Santen Pharmaceutical Co to acquire certain U.S. and Canadian commercial rights for a range of branded eyecare products.

The acquisition marks a significant milestone for Harrow, as it broadens the company’s product portfolio and enhances its presence in the U.S. ophthalmic pharmaceutical market. The deal includes several well-established products that cater to various ophthalmic needs, Flarex (fluorometholone acetate ophthalmic suspension) 0.1%; Natacyn (natamycin ophthalmic suspension) 5%; Tobradex ST (tobramycin and dexamethasone ophthalmic suspension) 0.3%/0.05%; Verkazia (cyclosporine ophthalmic emulsion) 0.1%; Zerviate (cetirizine ophthalmic solution) 0.24%; and Freshkote.

Read the full press release here.